+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 16 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the long-term safety, tolerability, and effectiveness of ML-007C-MA in adults with schizophrenia. This open-label Phase 2 study includes participants who have recently completed a previous related study or new participants enrolling directly. The study focuses on adults aged 18 to 65 diagnosed with schizophrenia who may benefit from ongoing pharmacotherapy and can maintain outpatient care. Participants will receive ML-007C-MA dosed at 2103 mg twice daily for up to 52 weeks. This single-group study does not involve placebo and assesses the medications impact over the treatment period. The study allows for continuous monitoring and adjustment based on the participants response and tolerability. During the study, participants will be involved in regular assessments to monitor safety and tolerability from the initial dose through the entire treatment period. Evaluations include clinical interviews, physical exams, ECGs, and laboratory tests to track any adverse effects or changes in health status. Researchers will also gather information from a reliable informant to support assessments. The total participation duration can be up to one year.

Age: 18Years - 65YearsAll GendersPhase 2
45 locations
P

Actively Recruiting

Major depressive disorder MDD is a mood disorder causing ongoing sadness and loss of interest, with emotional and physical symptoms such as irritability, difficulty focusing, tiredness, and changes in eating habits. Researchers are studying oral Icalcaprant, an investigational drug, to assess its effects on disease activity and side effects in adults currently experiencing a major depressive episode. Participants are randomly assigned to one of three groups two different doses of Icalcaprant or a placebo. They will take oral capsules once daily for 6 weeks, followed by a 30-day safety follow-up period. The study is conducted at about 35 sites across North America and involves approximately 195 adults. During the study, participants will attend regular visits at a hospital or clinic where medical assessments, blood tests, side effect checks, and questionnaires will be completed. Researchers will measure changes in depression severity using scales like the Montgomery-sberg Depression Rating Scale MADRS over about 6 weeks, and adverse events will be monitored for up to 10 weeks total.

Age: 18Years - 65YearsAll GendersPhase 2
33 locations
E

Actively Recruiting

Researchers are evaluating the drug TNX-102 SL to see if it helps treat adults with moderate to severe major depressive disorder MDD. This study aims to compare TNX-102 SL with a placebo to determine its effect on depression symptoms using a rating scale, and to assess the safety and medical issues participants may experience while taking the drug. Participants will take either 5.6 mg of TNX-102 SL two 2.8 mg tablets or matching placebo tablets every night at bedtime for six weeks. During the study, participants will visit the clinic every two weeks for checkups and tests to monitor their progress. Throughout the study, researchers will assess changes in depression severity using the MADRS score and other measures such as sleep disturbance and clinical impression scales. Safety and tolerability will also be monitored. Participation involves regular clinic visits over the six-week treatment period, with assessments occurring at baseline and every two weeks until the study concludes.

Age: 18Years +All GendersPhase 2
27 locations
P

Actively Recruiting

Researchers are conducting a pilot observational study to develop a minimally invasive wearable Remote Medication Monitor RMM that continuously and in real time measures methadone levels in the interstitial fluid ISF. This study aims to evaluate whether such a device can monitor medication adherence by showing if prescribed methadone doses have been taken. The study involves adults aged 18 to 70 who are prescribed methadone for chronic pain. The study consists of multiple aims involving biosample collection and pharmacokinetic monitoring. In Aim 1, biosamples of ISF and blood will be collected over up to 6 hours to assess if the RMM can detect methadone dose timing using ex vivo methods. Aim 2 involves inserting intradermal microneedle sensors into the skin to continuously monitor methadone levels via the RMM over 6 hours. Later aims include longer monitoring periods of up to 3 days to observe methadone and its metabolites in ISF. Participants will attend up to three visits involving ISF and blood sample collections, wearing the RMM device, and pharmacokinetic monitoring. Researchers will analyze methadone concentrations and metabolite levels using advanced laboratory techniques such as Liquid Chromatography-Mass Spectroscopy. The primary outcomes include correlations between methadone measurements in ISF and blood to evaluate the devices monitoring capabilities. The study is expected to run until April 2026.

Age: 18Years - 70YearsAll Genders
1 location
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of SPN-821, a novel oral drug, as an additional treatment for adults with major depressive disorder MDD. This phase 2, multicenter, randomized, double-blind, placebo-controlled study focuses on adults diagnosed with MDD who continue to experience symptoms despite stable antidepressant therapy. The study aims to assess improvements in depression severity using standardized rating scales. Participants are randomly assigned to receive either SPN-821 at a dose of 2400 mg three 800 mg tablets or matching placebo tablets, both administered twice a week alongside their current antidepressant medication. The study includes a 2-week screening period to confirm eligibility, followed by a 4-week treatment period where participants receive the assigned study tablets. After completing treatment, participants undergo a safety follow-up phone call one week later to monitor any ongoing effects. During the study, participants will have their depression symptoms evaluated using the Montgomery-sberg Depression Rating Scale MADRS and Clinical Global Impression-Severity CGI-S scale at baseline and Day 29. Safety assessments and monitoring occur throughout the trial and during the follow-up call. Overall, the study participation lasts approximately 7 weeks including screening, treatment, and follow-up to understand the impact of SPN-821 on depressive symptoms and safety in adults with MDD.

Age: 18Years - 70YearsAll GendersPhase 2
40 locations
P

Actively Recruiting

Researchers are evaluating the drug NBI-1117568 in adults with schizophrenia to determine if it can delay the return of symptoms after a stable response to treatment. This Phase 3, placebo-controlled study focuses on adults between 18 and 65 years old who have already shown improvement with antipsychotic therapy. The trial is designed to assess the safety and effectiveness of NBI-1117568 in preventing relapse. Participants first enter an open-label stabilization period during which all receive NBI-1117568. Following this, they are randomly assigned to continue receiving either NBI-1117568 or a placebo in a double-blind treatment period. Both NBI-1117568 and placebo are given as oral capsules. The study includes a parallel design comparing these two groups. Throughout the study, participants will be closely monitored for relapse of schizophrenia symptoms over approximately 30 weeks. Researchers will measure the time from randomization to relapse as the primary outcome. Safety and tolerability are also assessed during the trial. The total study duration extends until July 2029, with regular evaluations to understand how well participants maintain symptom control.

Age: 18Years - 65YearsAll GendersPhase 3
25 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of LB-102 in treating adult patients with Bipolar I Disorder who are currently experiencing a major depressive episode. This Phase 2, randomized, double-blind, placebo-controlled multicenter study aims to compare the effects of LB-102 against a placebo over a treatment period of six weeks. Participants will be randomly assigned in equal numbers to receive either LB-102 or a placebo once daily by mouth. LB-102 dosing starts at 25 mg daily for the first three weeks, with a possible increase to 50 mg daily from Week 4 based on clinical assessment scores. Patients on placebo will take one tablet daily for six weeks. Medication will be provided in weekly bottles, and both patients and study staff will be unaware of the treatment assignments. After completing the study treatment on Day 43, participants may resume antidepressant or mood stabilizer treatments if applicable. During the study, participants will undergo several assessments including measurement of depressive symptoms using the Montgomery sberg Depression Rating Scale MADRS-10 from baseline to Day 42. Researchers will also monitor adverse events and treatment-emergent mania symptoms using the Young Mania Rating Scale YMRS up to Day 56. The study includes regular visits for medication dispensing and clinical evaluations over the six-week treatment period, with participant health and safety closely observed throughout.

Age: 18Years - 65YearsAll GendersPhase 2
26 locations
G

Actively Recruiting

Researchers are studying the long-term safety of the drug NBI-1117568 in adults diagnosed with schizophrenia. This phase 3, open-label trial aims to understand how well participants tolerate this medication when taken daily over an extended period. The study is sponsored by Neurocrine Biosciences and focuses on monitoring treatment-emergent adverse events. Participants will receive NBI-1117568 orally once a day for up to 36 months. This single-group study does not include a placebo or comparator arm. The treatment duration allows researchers to assess safety and tolerability during continuous daily use over three years. During the study, participants will have regular assessments to monitor any adverse effects associated with the drug. Researchers will track the number of participants experiencing treatment-emergent adverse events throughout the 36-month period. The study includes adults aged 18 to 65 years who have a primary diagnosis of schizophrenia and reside in stable housing, and it excludes those with certain medical conditions or substance use disorders. Participants will be closely observed to ensure adherence to the study protocol and safety monitoring.

Age: 18Years - 65YearsAll GendersPhase 3
61 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness of iloperidone long-acting injection LAI compared to a placebo in preventing worsening symptoms in adults with schizophrenia. This is a Phase 3, double-blind, randomized withdrawal study sponsored by Vanda Pharmaceuticals, aiming to understand how well iloperidone LAI maintains symptom control in this population. The study begins with a 12-week stabilization phase where all participants receive open-label iloperidone, first as oral tablets for six weeks, followed by long-acting intramuscular injections for another six weeks. After stabilization, participants are randomly assigned to receive either iloperidone LAI or a matching placebo injection every few weeks for up to 52 weeks in a double-blind manner. Participants will be closely monitored throughout the study, including during the stabilization and randomized phases, to track the time until symptoms worsen. Researchers will assess changes in schizophrenia symptoms over the 52-week post-randomization period. Safety and adherence to the study drug will be observed, providing valuable information on the treatments ability to maintain symptom stability over time.

Age: 18Years - 65YearsAll GendersPhase 3
22 locations
P

Actively Recruiting

The trial investigates the use of KarXT XanomelineTrospium Chloride for preventing relapse in adults diagnosed with schizophrenia. Participants must have had schizophrenia for at least one year with recent hospitalization and persistent symptoms, evaluated by specific psychiatric scales. This Phase 3 randomized, double-blind, placebo-controlled study aims to assess how well KarXT maintains symptom control compared to placebo. Participants are randomly assigned to receive either KarXT or a placebo with specified doses given on set days. The study monitors participants over a period of up to approximately 43 weeks after randomization to evaluate relapse prevention. All treatments and follow-ups are masked to ensure unbiased assessment. During the study, participants undergo regular evaluations including psychiatric assessments using PANSS and CGI-S scores to measure symptom severity and relapse events. Safety is monitored through tracking of adverse events and special interest symptoms. The primary outcome measures the time from randomization to the first relapse. The total participation duration spans several months, with ongoing safety and efficacy assessments throughout the study period.

Age: 18Years - 65YearsAll GendersPhase 3
54 locations

1-10 of 16

1